Cargando…

Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage

This report describes a cirrhotic female patient with no history of bleeding or other gastrointestinal disorder who experienced fatal gastrointestinal bleeding (GIB) after taking apixaban [which is a direct oral anticoagulant (DOAC)] for one month for management of chronic nonvalvular atrial fibrill...

Descripción completa

Detalles Bibliográficos
Autor principal: Yen, Hung-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903885/
https://www.ncbi.nlm.nih.gov/pubmed/31886064
http://dx.doi.org/10.7759/cureus.6126
_version_ 1783477920914735104
author Yen, Hung-Wen
author_facet Yen, Hung-Wen
author_sort Yen, Hung-Wen
collection PubMed
description This report describes a cirrhotic female patient with no history of bleeding or other gastrointestinal disorder who experienced fatal gastrointestinal bleeding (GIB) after taking apixaban [which is a direct oral anticoagulant (DOAC)] for one month for management of chronic nonvalvular atrial fibrillation. The use of apixaban, coupled with the predilection for hemorrhage in cirrhotic patients, most likely contributed to her fatal GIB. Caution should be exercised in considering apixaban and potentially other members of the DOAC class for the treatment of cirrhotic patients until further research can explore the safety of DOAC therapy in cirrhotic patients.
format Online
Article
Text
id pubmed-6903885
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-69038852019-12-29 Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage Yen, Hung-Wen Cureus Hematology This report describes a cirrhotic female patient with no history of bleeding or other gastrointestinal disorder who experienced fatal gastrointestinal bleeding (GIB) after taking apixaban [which is a direct oral anticoagulant (DOAC)] for one month for management of chronic nonvalvular atrial fibrillation. The use of apixaban, coupled with the predilection for hemorrhage in cirrhotic patients, most likely contributed to her fatal GIB. Caution should be exercised in considering apixaban and potentially other members of the DOAC class for the treatment of cirrhotic patients until further research can explore the safety of DOAC therapy in cirrhotic patients. Cureus 2019-11-11 /pmc/articles/PMC6903885/ /pubmed/31886064 http://dx.doi.org/10.7759/cureus.6126 Text en Copyright © 2019, Yen et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Hematology
Yen, Hung-Wen
Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title_full Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title_fullStr Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title_full_unstemmed Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title_short Fatal Nonvariceal Gastrointestinal Bleeding in a Cirrhotic Patient Taking Apixaban with No History of Hemorrhage
title_sort fatal nonvariceal gastrointestinal bleeding in a cirrhotic patient taking apixaban with no history of hemorrhage
topic Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903885/
https://www.ncbi.nlm.nih.gov/pubmed/31886064
http://dx.doi.org/10.7759/cureus.6126
work_keys_str_mv AT yenhungwen fatalnonvaricealgastrointestinalbleedinginacirrhoticpatienttakingapixabanwithnohistoryofhemorrhage